Advectus Life Sciences Begins Preclinical Trials of P80DOX-NP

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

VANCOUVER, Canada-Ad-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure

VANCOUVER, Canada—Ad-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure formulation P80DOX-NP on rodent brain metastases arising from lung, breast, renal cell, and colon cancers, and melanoma, the company announced.

P80DOX-NP is a novel method for the delivery of doxorubicin across the blood-brain barrier. The randomized, placebo-controlled study will measure survival as a surrogate for intracranial tumor progression/regression.

Articles in this issue
Medicaid Gives New Protections to Beneficiaries in Managed Care Plans
Prostate Cancer Cell Line Vaccine Promising in Phase II Trial
MoAb Targeting Death Receptor in Breast Cancer
Hanford I-131 Releases Did Not Increase Thyroid Cancer Risk
Chemo/Rituximab Is Effective as First-Line CLL Therapy
Diagnostic Dilemma
Viral Agent ONYX-015 Targets p53-Deficient Cancer Cells
Program Educates Teens About Testicular Cancer Self-Exam
Better Colon Cancer Imaging With PET/CT Than With PET Alone
Delayed Lung Cancer Screening Trial to Begin Enrollment 50,000 Subjects
Results Similar With Weekly or Every-3-Week Irinotecan Dosing Regimens
Single-Dose Palonosetron Prevents Acute, Delayed Emesis
Adjuvant Chemo Controversy in Microsatellite Unstable Colon Cancer
Radiolabeled TNT MoAb Effective in Inoperable Lung Cancer
Multidetector CT Finds Peritoneal Ovarian Cancer Metastasis

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Related Content
Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.

In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.